Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar, et al.
Journal of Allergy and Clinical Immunology (2018) Vol. 143, Iss. 1, pp. 155-172
Open Access | Times Cited: 543

Showing 1-25 of 543 citing articles:

Atopic dermatitis endotypes and implications for targeted therapeutics
Tali Czarnowicki, Helen He, James G. Krueger, et al.
Journal of Allergy and Clinical Immunology (2019) Vol. 143, Iss. 1, pp. 1-11
Open Access | Times Cited: 483
Type 2 immunity in the skin and lungs
Cezmi A. Akdiş, Peter D. Arkwright, Marie‐Charlotte Brüggen, et al.
Allergy (2020) Vol. 75, Iss. 7, pp. 1582-1605
Open Access | Times Cited: 415
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, et al.
JAMA Dermatology (2019) Vol. 156, Iss. 1, pp. 44-44
Open Access | Times Cited: 410
Conjunctivitis in dupilumab clinical trials
Bolanle Akinlade, Emma Guttman‐Yassky, Marjolein de Bruin‐Weller, et al.
British Journal of Dermatology (2019) Vol. 181, Iss. 3, pp. 459-473
Open Access | Times Cited: 355
Mechanisms of Dupilumab
Hani Harb, Talal A. Chatila
Clinical & Experimental Allergy (2019) Vol. 50, Iss. 1, pp. 5-14
Open Access | Times Cited: 355
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 12, pp. 1101-1112
Open Access | Times Cited: 338
Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis
Gabsik Yang, Jin Kyung Seok, Han Chang Kang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2867-2867
Open Access | Times Cited: 302
Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis
Masutaka Furue
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5382-5382
Open Access | Times Cited: 268
Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection
Anna Fishbein, Jonathan I. Silverberg, Eve J. Wilson, et al.
The Journal of Allergy and Clinical Immunology In Practice (2019) Vol. 8, Iss. 1, pp. 91-101
Open Access | Times Cited: 241
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran, Diamant Thaçi, Lisa A. Beck, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 2, pp. 377-388
Open Access | Times Cited: 222
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Yael Renert‐Yuval, Jacob P. Thyssen, Robert Bissonnette, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 147, Iss. 4, pp. 1174-1190.e1
Open Access | Times Cited: 222
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis
Anne‐Sofie Halling, Nikolai Loft, Jonathan I. Silverberg, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 139-147
Closed Access | Times Cited: 216
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
Emma Guttman‐Yassky, Ana B. Pavel, Lisa Zhou, et al.
Journal of Allergy and Clinical Immunology (2019) Vol. 144, Iss. 2, pp. 482-493.e7
Open Access | Times Cited: 183
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
Chris Callewaert, Teruaki Nakatsuji, Rob Knight, et al.
Journal of Investigative Dermatology (2019) Vol. 140, Iss. 1, pp. 191-202.e7
Open Access | Times Cited: 170
Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis
Emma Guttman‐Yassky, Aisleen Diaz, Ana B. Pavel, et al.
JAMA Dermatology (2019) Vol. 155, Iss. 12, pp. 1358-1358
Open Access | Times Cited: 152
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis
Helen He, Robert Bissonnette, Jianni Wu, et al.
Journal of Allergy and Clinical Immunology (2020) Vol. 147, Iss. 1, pp. 199-212
Closed Access | Times Cited: 149
Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents
Thomas A. Luger, Masayuki Amagai, Brigitte Dréno, et al.
Journal of Dermatological Science (2021) Vol. 102, Iss. 3, pp. 142-157
Closed Access | Times Cited: 149
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Lisa A. Beck, Michael J. Cork, Masayuki Amagai, et al.
JID Innovations (2022) Vol. 2, Iss. 5, pp. 100131-100131
Open Access | Times Cited: 140
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Jennifer D. Hamilton, Sivan Harel, Brian N. Swanson, et al.
Clinical & Experimental Allergy (2021) Vol. 51, Iss. 7, pp. 915-931
Open Access | Times Cited: 124
Persistence of mature dendritic cells, T H 2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade
Christine Bangert, Katharina Rindler, Thomas Krausgruber, et al.
Science Immunology (2021) Vol. 6, Iss. 55
Closed Access | Times Cited: 118
The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults
Yael Renert‐Yuval, Ester Del Duca, Ana B. Pavel, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 1, pp. 148-163
Open Access | Times Cited: 115
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Gil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.
Nature Medicine (2023) Vol. 29, Iss. 5, pp. 1180-1190
Open Access | Times Cited: 115
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
Thanaporn Ratchataswan, Tina Banzon, Jacob P. Thyssen, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 3, pp. 1053-1065
Open Access | Times Cited: 105
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
Derek K. Chu, Lynda C. Schneider, Rachel Netahe Asiniwasis, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 3, pp. 274-312
Open Access | Times Cited: 94
Revisiting the Roles of Filaggrin in Atopic Dermatitis
Verena Moosbrugger‐Martinz, Corinne Leprince, Marie‐Claire Méchin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5318-5318
Open Access | Times Cited: 85
Page 1 - Next Page

Scroll to top